Amarin corporation plc- adr AMRN.US 總覽分析
)AMRN 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分較低，若以價值投資為目標，已經有長期投資部位可能需陸續減碼
AMRN 近期報酬表現
0.10%
Amarin corporation plc- adr
4.57%
同產業平均
3.26%
S&P500
與 AMRN 同產業的標的表現
- ABVX Abivax sa - adr價值 -趨勢 3 分波段 4 分籌碼 3 分股利 1 分查看更多
AMRN 公司資訊
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.